Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn with a Recent History of Gestational DiabETes Mellitus: the SWEET Study

NCT04873050 is registered in ClinicalTrials.gov with Woman's as lead sponsor.

NCT NCT04873050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04873050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn with a Recent History of Gestational DiabETes Mellitus: the SWEET Study
Lead sponsor
Woman's
Phase
Phase 4
Overall status
Recruiting
Start date
January 13, 2022
Completion date
March 1, 2026
Enrollment
102 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postpartum disorder, pre diabetes